

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

1x50, 1x100, 1x 200/200, 1x 200/250, 1x250, 5x50, 5x100, 5x200/200, 5x200/250, 5x250 ml carton box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hyogen emulsion for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each 2 ml dose contains:

Inactivated *Mycoplasma hyopneumoniae* 2940 strain: min.328 ELISA Units

3. PACKAGE SIZE

50 ml (25 doses)
100 ml (50 doses)
200 ml (100 doses) in 200 ml bottle
200 ml (100 doses) in 250 ml bottle
250 ml (125 doses)
5x50 ml (5x25 doses)
5x100 ml (5x50 doses)
5x200 ml (5x100 doses) in 200 ml bottles
5x200 ml (5x100 doses) in 250 ml bottles
5x250 ml (5x125 doses)

4. TARGET SPECIES

Pigs (for fattening)

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Intramuscular use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use by 10 hours.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd

14. MARKETING AUTHORISATION NUMBERS

Vm 15052/3013

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

100, 200 or 250 ml bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hyogen emulsion for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each 2 ml dose contains:

Inactivated *Mycoplasma hyopneumoniae* 2940 strain: min. 328 ELISA Units

3. TARGET SPECIES

Pigs (for fattening)

4. ROUTES OF ADMINISTRATION

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal period: Zero days

6. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use by 10 hours.

7. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator.

Do not freeze.

Protect from light.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

50 ml bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hyogen

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each 2 ml dose contains:

Inactivated *Mycoplasma hyopneumoniae* 2940 strain: min. 328 ELISA Units

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use by 10 hours.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Hyogen emulsion for injection

2. Composition

Each 2 ml dose contains:

Active substance:

Inactivated *Mycoplasma hyopneumoniae* 2940 strain: min. 328 ELISA Units

Adjuvants:

| | |
|--------------------------------|--------------------------------------|
| Light liquid paraffin | 187 µl |
| <i>Escherichia coli</i> J5 LPS | min. 594 - max. 38000 Endotoxin unit |

Excipient:

| | |
|------------|----------------|
| Thiomersal | 30.6 - 58.5 µg |
|------------|----------------|

Off-white, homogeneous emulsion.

3. Target species

Pigs

4. Indications for use

For the active immunization of fattening pigs from 3 weeks of age to reduce the occurrence and severity of lung lesions caused by *Mycoplasma hyopneumoniae* infection.

Onset of immunity: 3 weeks after vaccination

Duration of immunity: 26 weeks after vaccination

5. Contraindications

None

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

The data available are not sufficient to exclude the interaction of maternally derived antibodies against *Mycoplasma hyopneumoniae* with vaccine uptake. Interaction with maternally derived antibodies is known and should be taken into consideration. It is recommended to delay vaccination in piglets with residual MDA against *Mycoplasma hyopneumoniae* at the age of 3 weeks.

Pregnancy and lactation:
Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Circovac and administered to piglets at one injection site. Vaccinate piglets from 3 weeks of age.

Onset of immunity: 3 weeks after vaccination when mixed with Circovac
Duration of immunity: 23 weeks when mixed with Circovac.

In case of mixing with Circovac, slight and transient local reactions may occur very commonly after the administration, mainly swelling (0.5 cm - 5 cm), mild pain and redness as well as in some cases oedema. These reactions resolve spontaneously within maximum 4 days. Transient lethargy may occur very commonly on the day of vaccination which resolves spontaneously within 1-2 days. An increase in individual rectal temperature of up to 2.5°C may occur commonly lasting less than 24 hours. The above adverse reactions were observed in clinical studies.

The product literature of Circovac should be consulted before mixed administration.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product, except when mixed with Circovac. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

As the vaccine is inactivated, studies investigating the safety of an overdose administration are not required.

Major incompatibilities:

Do not mix with any other veterinary medicinal product, except Circovac.

7. Adverse events

Pigs (for fattening)

| | |
|--|---|
| Very common (>1 animal / 10 animals treated): | Elevated temperature ¹ Injection site swelling ² |
| Uncommon (1 to 10 animals / 1,000 animals treated): | Hypersensitivity reaction ³ |
| Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Anaphylactic shock ⁴ |

¹ Increase in body temperature (average 1.3 °C, in individual pigs up to 2 °C) on the day of vaccination, which resolves within one day.

² A local injection site swelling up to 5 cm in diameter, lasting up to three days. These reactions do not need further treatment.

³ Immediate mild hypersensitivity-like reactions after vaccination, resulting in transient clinical signs such as vomiting.

⁴ Serious anaphylactic-type reactions (shock, recumbency) which may be fatal. Such reactions require prompt symptomatic treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a product.

If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.” {national system details}

8. Dosage for each species, routes and method of administration

Intramuscular use. Vaccinate pigs in the side of their neck. Administer a single dose of 2 ml from 3 weeks of age.

9. Advice on correct administration

Shake well before use.
Use sterile syringe and needle, respect aseptic conditions of vaccination.

When Hyogen is used alone:

Intramuscular use.
Vaccinate pigs in the side of their neck.
Administer a single dose of 2 ml from 3 weeks of age.


When Hyogen is mixed with Circovac:

The mixed use is restricted to the 100 doses (200 ml) presentations of Hyogen and to the 100 doses presentations (50 ml of reconstituted vaccine) of Circovac.

Piglets from 3 weeks of age:

| Hyogen | Circovac |
|--|--|
| 100 doses (200 ml of vaccine) in 250 ml bottle | 100 doses for piglets (50 ml of reconstituted suspension + emulsion) |

Vaccine devices should be used under aseptic conditions and in accordance with the device instructions provided by the manufacturer.
Prepare Circovac by vigorously shaking the vial of antigen suspension and injecting its content into the vial of emulsion containing adjuvant.
Mix 200 ml of Hyogen and 50 ml of Circovac and shake gently until a homogeneous white emulsion is obtained.
Administer one 2.5 ml dose of the mixture by intramuscular injection, in the side of the neck.
Use the entire vaccine mixture immediately after mixing.



10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label.

The expiry date refers to the last day of that month.

Shelf life after first opening the container: 10 hours.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater <or household waste>.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 15052/3013

Low density polyethylene bottle of 50, 100, 200 or 250 ml volume, sealed with siliconed, oil-resistant, nitrile rubber stopper and aluminium cap, in a cardboard box.

1x50 ml (1x25 doses),
1x100 ml (1x50 doses),
1x200 ml (1x100 doses) in 200 ml bottle,
1x200 ml (1x100 doses) in 250 ml bottle,
1x250 ml (1x125 doses),
5x50 ml (5x25 doses),
5x100 ml (5x50 doses),
5x200 ml (5x100 doses) in 200 ml bottles,
5x200 ml (5x100 doses) in 250 ml bottles
5x250 ml (5x125 doses).

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Ceva Animal Health Ltd
Explorer House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0HH
United Kingdom

Email: pharmacovigilance@ceva.com
Phone number: +800 35 22 11 51

Manufacturer responsible for batch release:

Ceva-Phylaxia Co. Ltd.
1107 Budapest Szállás u. 5.
Hungary

Approved 28 April 2024

A handwritten signature in black ink, appearing to read 'A. Hunter.', is positioned below the approval date.